SCHEMBL6155038

SCHEMBL6155038

COc1cc(NC2CCN(S(C)(=O)=O)CC2)ccc1C(N)=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 8/20 0.52
CDK4 P11802 8/20 0.52
CCND1 P24385 8/20 0.52
CDK2 P24941 8/20 0.52
SMN1; SMN2 Q16637 1/20 0.49
JAK2 O60674 1/20 0.48
JAK3 P52333 1/20 0.48
HTT P42858 1/20 0.46
SYK P43405 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CASK O14936 1/20 0.45
ROCK2 O75116 1/20 0.45
CDKL5 O76039 1/20 0.45
STK10 O94804 1/20 0.45
CDK14 O94921 1/20 0.45
ABL1 P00519 1/20 0.45
EGFR P00533 1/20 0.45
MAK P20794 1/20 0.45
CDK11B P21127 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6154241 0.86 CCR6 (0.57) CDK2SMN1; SMN2HTTMEN1KMT2A
SCHEMBL6154425 0.86 EHMT2 (0.50) CDK1SMN1; SMN2JAK2JAK3GAA
SCHEMBL6154337 0.84 MAPT (0.52) CDK1CDK4CCND1CDK2JAK2
SCHEMBL6154287 0.82 PARP15 (0.55) SMN1; SMN2SYKGAA
SCHEMBL6154109 0.81 SMN1; SMN2 (0.62) SMN1; SMN2MEN1KMT2AHTR4
SCHEMBL6153579 0.81 KIT (0.60) SYKMEN1KMT2AROCK2ROCK1
SCHEMBL6153345 0.81 KIT (0.60) SYKMEN1KMT2AROCK2ROCK1
SCHEMBL6153341 0.81 KIT (0.60) SYKMEN1KMT2AROCK2ROCK1
SCHEMBL6154491 0.80 KIT (0.47) SMN1; SMN2SYKMEN1KMT2AGAA
SCHEMBL6153322 0.80 FLT3 (0.47) CDK4CDK2SMN1; SMN2JAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 CDK1 408/4885CDK4 2131/4885CCND1 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.